EMAS position statement: Testosterone replacement therapy in the aging male

Dimopoulou, Christina; Ceausu, Iuliana; Depypere, Herman; Lambrinoudaki, Irene; Mueck, Alfred; Perez-Lopez, Faustino; Rees, Margaret; van der Schouw, Yvonne; Senturk, Levent; Simonsini, Tommaso; Stevenson, John; Stute, Petra; Goulis, Dimitrios

doi:10.1016/j.maturitas.2015.11.003

EMAS position statement: Testosterone replacement therapy in the aging male

Atıf İçin Kopyala

Dimopoulou C., Ceausu I., Depypere H., Lambrinoudaki I., Mueck A., Perez-Lopez F. R., ...Daha Fazla

MATURITAS, cilt.84, ss.94-99, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 84
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.maturitas.2015.11.003
Dergi Adı: MATURITAS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.94-99
İstanbul Üniversitesi Adresli: Evet

Özet

Introduction: Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, characterized by the presence of symptoms (most usually of a sexual nature, such as decreased libido, decreased spontaneous erections and erectile dysfunction) and signs, in combination with low serum testosterone concentrations. Whether testosterone replacement therapy (TRT) should be offered to those individuals is still under extensive debate.